Chamber and committees

The 2021-22 Scottish Budget provides £1.1 billion for investment in general medical services, in addition to £11.6 billion for our frontline NHS Boards.

General medical services includes general practice investment and a wider range of additional and linked services in the community, including pharmacy, mental health nursing, dental and ophthalmic.

A publication by Public Health Scotland on 26th January 2021 showed the total number of GPs in Scotland was 5,134 as at 30th September 2020, a rise of 89 compared to 2019.

Public Health Scotland are currently analysing data collected from the 2019 Workforce Survey, which will show the Whole Time Equivalent (WTE) figure for GPs in Scotland. Scottish Government are planning to collect WTE data on an annual basis going forward.

The Scottish Government is supportive of the work of Versus Arthritis including the six-point support package. In support of this the Minister for Public Health, Women’s Health and Sport is due to meet with representatives of Versus Arthritis soon to discuss the initiative.

We are working in collaboration with the organisation to ensure that patients on waiting lists receive good communication and relevant support while they await treatment. This work will be ongoing with essential collaboration with patients, carers and providers including the National Advisory Committee for Chronic Pain NACCP.

The legislative changes recommended by the review are being introduced via the Integrated Authorisation Framework regulations, however the progression of the regulations was paused due to Covid-19. We have now recommenced taking this work forward and a consultation process will take place in the coming months.

The study report on the impacts of sewage sludge on the environment and human health is scheduled to be published later this year.

Statistics for the cervical screening programme that will allow comparisons with pre-Covid-19 pandemic uptake are due to be published by Public Health Scotland on 1 September 2021.

Comparable data on national performance for uptake in the breast and bowel screening programmes that will allow comparisons between uptake before and after the COVID-19 pandemic will be made available in 2022. NHS National Services Division advise that recent uptake in the bowel screening programme is similar to pre-pandemic levels at around 67%. Breast screening uptake is measured on an annual and 3 year cycle with current indications that uptake is running at an average of 80% across the whole programme, which is higher than uptake prior to the pandemic.

The bowel, breast and cervical screening programmes were paused in March last year, and restarted last summer with the initial focus on higher-risk screening participants and those whose appointments were affected by the pause.

The bowel screening programme is currently sending home test kits at the same rate as before the pandemic, and no one is waiting for an invitation.

The breast screening programme is recovering, although infection control measures, including physical distancing and personal protective equipment, mean there are considerable capacity challenges. At this time, we do not have data on the number of people affected by the pause; however, we do know that slippage varies across health boards. The National Screening Oversight, the Scottish Screening Committee and the Breast Screening Programme Board continue to work with health boards to increase the number of breast screening appointments available.

Covid-19 also continues to present challenges in the cervical screening programme. However, prompts and reminders are being issued at pre-Covid rates. Estimates suggest that 5,786 invitations have not yet issued to people affected by the pause, but it should be stressed that this will be for a range of reasons, including participants being excluded from the programme after it restarted, or taking the opportunity to be screened at their GP ahead of their scheduled prompt to make an appointment.

The bowel, breast and cervical screening programmes are governed by their respective programme boards, as well as the National Screening Oversight and the Scottish Screening Committee. They monitor and evaluate performance, including uptake rates, against a set of standards developed by Healthcare Improvement Scotland.

Additional information has been provided over the course of the pandemic, to reassure people that travel to attend a screening appointment during lockdown was classed as essential and that appropriate infection control measures are in place, so they can feel confident about attending.

In addition to providing information on NHS Inform, each programme has developed tailored communications to recognise additional concerns and challenges caused by the pandemic, and each continues to take steps to reduce barriers to screening and increase uptake.

The bowel screening programme includes supplementary information in home test kits, and has a dedicated helpline to answer all questions. Since the breast screening programme restarted last summer, breast screening centres have been contacting participants ahead of their appointments to confirm their intention to attend. To ensure sufficient capacity in the cervical screening programme to allow uptake of invitations following the pause, the Scottish Government provided just under £1 million to support capacity in sample taking and colposcopy services. To raise awareness and increase uptake we supported social media messaging during Cervical Screening Awareness week in June. Later this year, the Scottish Government will also be launching a campaign to communicate the benefits of cervical screening.

The Scottish Government recognises that the Covid-19 pandemic may have exacerbated inequalities in screening uptake, and we have committed £2 million over the next two years, to build a programme of evidence-based, sustainable and scalable projects that tackle inequalities in a systemic way.

The Scottish Government has provided in-kind support to Valneva via Scottish Enterprise. There has been no financial investment made in this facility by the Scottish Government.

The decision for any company to list on the Nasdaq is a commercial decision made by the organisation itself and the company already has a stock exchange, listing on the Paris Bourse (Euronext).

Vaccines Taskforce and BEIS have provided the following commentary that the UK Government has supported Valneva by providing funding for its early clinical trials and has also made a multi-million-pound investment to upgrade and expand Valneva’s Livingston manufacturing facility, as part of its supply agreement for COVID-19 vaccines.

Our overall vision is for everyone with rehabilitation needs to be able to access the care and support they need to live well, on their own terms. Work is underway to deliver the Framework for supporting people through Recovery and Rehabilitation during and after the COVID-19 Pandemic. This puts in place clear principles, priorities and objectives to support planning to meet increasing demand and to provide high quality person-centred rehabilitation in different settings.

In addition, as part of our Programme for Government stroke commitments to develop a programme to improve stroke pathways and services, recommendations are being developed to ensure that all those who experience communication disorders following a stroke are assessed by a speech and language therapist and; are provided with an individualised rehabilitation programme using a range of evidence based interventions.

This will be evaluated as part of the national stroke care audit and services within NHS Health and Social Care Partnerships will be reviewed on an annual basis by the Scottish Government Stroke Improvement Team.